Loading…
Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment
A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterf...
Saved in:
| Published in: | In vivo (Athens) 2017-07, Vol.31 (4), p.723-729 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c387t-abe26fbaf24caba24c72c393623495e22d7da823dba39f8d31e41254892ebde73 |
|---|---|
| cites | |
| container_end_page | 729 |
| container_issue | 4 |
| container_start_page | 723 |
| container_title | In vivo (Athens) |
| container_volume | 31 |
| creator | Le, Puo-Hsien Liang, Kung-Hao Chang, Ming-Ling Hsu, Chao-Wei Chen, Yi-Cheng Lin, Chih-Lang Lin, Wey-Ran Lai, Ming-Wei Yeh, Chau-Ting |
| description | A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy.
The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B.
Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p |
| doi_str_mv | 10.21873/invivo.11121 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5566930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1914289356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-abe26fbaf24caba24c72c393623495e22d7da823dba39f8d31e41254892ebde73</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhq0K1C84ckU-ckmJ7SSOL0iwoi3SClZVOVuOM9kMSuxgexftD-B_1-qWqlxmRjPPvDPSS8g7Vl5x1krxEd0e9_6KMcbZCTlnUrFC1pV69aI-Ixcx_irLRpYlPyVnvG1qXlXynPxdTejQmoluAvRokw-RDj7Q77BLwS8jTkXyxfowL6O3hwT0ziT0dDUat4VI0dFNboBLkf7BNOZB8FmQ3sKS-wkj_ULvwALu0W3pBrboEoQBMkXvA5g059035PVgpghvn_Il-Xn99X51W6x_3HxbfV4XVrQyFaYD3gydGXhlTWdylNwKJRouKlUD573sTctF3xmhhrYXDCrG66pVHLoepLgkn466y66bobf5dDCTXgLOJhy0N6j_nzgc9dbvdV03jRJlFvjwJBD87x3EpGeMFqbJOPC7qJliFW-VqJuMFkfUBh9jgOH5DCv1o3X6aJ1-tC7z71_-9kz_80o8AJeEmpQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1914289356</pqid></control><display><type>article</type><title>Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment</title><source>PubMed (Medline)</source><creator>Le, Puo-Hsien ; Liang, Kung-Hao ; Chang, Ming-Ling ; Hsu, Chao-Wei ; Chen, Yi-Cheng ; Lin, Chih-Lang ; Lin, Wey-Ran ; Lai, Ming-Wei ; Yeh, Chau-Ting</creator><creatorcontrib>Le, Puo-Hsien ; Liang, Kung-Hao ; Chang, Ming-Ling ; Hsu, Chao-Wei ; Chen, Yi-Cheng ; Lin, Chih-Lang ; Lin, Wey-Ran ; Lai, Ming-Wei ; Yeh, Chau-Ting</creatorcontrib><description>A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy.
The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B.
Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p<0.001).
Pretreatment NLR, hemoglobin and hepatitis B surface antigen level in combination, effectively predicted NLR changes following peginterferon treatment.</description><identifier>ISSN: 1791-7549</identifier><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>DOI: 10.21873/invivo.11121</identifier><identifier>PMID: 28652447</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adult ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - virology ; Female ; Hemoglobins - isolation & purification ; Hepatitis B Surface Antigens - isolation & purification ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Liver Neoplasms - blood ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Lymphocyte Count ; Lymphocytes - drug effects ; Lymphocytes - pathology ; Male ; Middle Aged ; Neutrophils - drug effects ; Neutrophils - pathology ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - adverse effects ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - adverse effects</subject><ispartof>In vivo (Athens), 2017-07, Vol.31 (4), p.723-729</ispartof><rights>Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright 2017, International Institute of Anticancer Research 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-abe26fbaf24caba24c72c393623495e22d7da823dba39f8d31e41254892ebde73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566930/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566930/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28652447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Le, Puo-Hsien</creatorcontrib><creatorcontrib>Liang, Kung-Hao</creatorcontrib><creatorcontrib>Chang, Ming-Ling</creatorcontrib><creatorcontrib>Hsu, Chao-Wei</creatorcontrib><creatorcontrib>Chen, Yi-Cheng</creatorcontrib><creatorcontrib>Lin, Chih-Lang</creatorcontrib><creatorcontrib>Lin, Wey-Ran</creatorcontrib><creatorcontrib>Lai, Ming-Wei</creatorcontrib><creatorcontrib>Yeh, Chau-Ting</creatorcontrib><title>Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy.
The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B.
Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p<0.001).
Pretreatment NLR, hemoglobin and hepatitis B surface antigen level in combination, effectively predicted NLR changes following peginterferon treatment.</description><subject>Adult</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Female</subject><subject>Hemoglobins - isolation & purification</subject><subject>Hepatitis B Surface Antigens - isolation & purification</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphocyte Count</subject><subject>Lymphocytes - drug effects</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neutrophils - drug effects</subject><subject>Neutrophils - pathology</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - adverse effects</subject><issn>1791-7549</issn><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkU1v1DAQhq0K1C84ckU-ckmJ7SSOL0iwoi3SClZVOVuOM9kMSuxgexftD-B_1-qWqlxmRjPPvDPSS8g7Vl5x1krxEd0e9_6KMcbZCTlnUrFC1pV69aI-Ixcx_irLRpYlPyVnvG1qXlXynPxdTejQmoluAvRokw-RDj7Q77BLwS8jTkXyxfowL6O3hwT0ziT0dDUat4VI0dFNboBLkf7BNOZB8FmQ3sKS-wkj_ULvwALu0W3pBrboEoQBMkXvA5g059035PVgpghvn_Il-Xn99X51W6x_3HxbfV4XVrQyFaYD3gydGXhlTWdylNwKJRouKlUD573sTctF3xmhhrYXDCrG66pVHLoepLgkn466y66bobf5dDCTXgLOJhy0N6j_nzgc9dbvdV03jRJlFvjwJBD87x3EpGeMFqbJOPC7qJliFW-VqJuMFkfUBh9jgOH5DCv1o3X6aJ1-tC7z71_-9kz_80o8AJeEmpQ</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Le, Puo-Hsien</creator><creator>Liang, Kung-Hao</creator><creator>Chang, Ming-Ling</creator><creator>Hsu, Chao-Wei</creator><creator>Chen, Yi-Cheng</creator><creator>Lin, Chih-Lang</creator><creator>Lin, Wey-Ran</creator><creator>Lai, Ming-Wei</creator><creator>Yeh, Chau-Ting</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170701</creationdate><title>Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment</title><author>Le, Puo-Hsien ; Liang, Kung-Hao ; Chang, Ming-Ling ; Hsu, Chao-Wei ; Chen, Yi-Cheng ; Lin, Chih-Lang ; Lin, Wey-Ran ; Lai, Ming-Wei ; Yeh, Chau-Ting</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-abe26fbaf24caba24c72c393623495e22d7da823dba39f8d31e41254892ebde73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Female</topic><topic>Hemoglobins - isolation & purification</topic><topic>Hepatitis B Surface Antigens - isolation & purification</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphocyte Count</topic><topic>Lymphocytes - drug effects</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neutrophils - drug effects</topic><topic>Neutrophils - pathology</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le, Puo-Hsien</creatorcontrib><creatorcontrib>Liang, Kung-Hao</creatorcontrib><creatorcontrib>Chang, Ming-Ling</creatorcontrib><creatorcontrib>Hsu, Chao-Wei</creatorcontrib><creatorcontrib>Chen, Yi-Cheng</creatorcontrib><creatorcontrib>Lin, Chih-Lang</creatorcontrib><creatorcontrib>Lin, Wey-Ran</creatorcontrib><creatorcontrib>Lai, Ming-Wei</creatorcontrib><creatorcontrib>Yeh, Chau-Ting</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le, Puo-Hsien</au><au>Liang, Kung-Hao</au><au>Chang, Ming-Ling</au><au>Hsu, Chao-Wei</au><au>Chen, Yi-Cheng</au><au>Lin, Chih-Lang</au><au>Lin, Wey-Ran</au><au>Lai, Ming-Wei</au><au>Yeh, Chau-Ting</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>31</volume><issue>4</issue><spage>723</spage><epage>729</epage><pages>723-729</pages><issn>1791-7549</issn><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>A lower neutrophil-to-lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy.
The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B.
Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p<0.001).
Pretreatment NLR, hemoglobin and hepatitis B surface antigen level in combination, effectively predicted NLR changes following peginterferon treatment.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>28652447</pmid><doi>10.21873/invivo.11121</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1791-7549 |
| ispartof | In vivo (Athens), 2017-07, Vol.31 (4), p.723-729 |
| issn | 1791-7549 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5566930 |
| source | PubMed (Medline) |
| subjects | Adult Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - virology Female Hemoglobins - isolation & purification Hepatitis B Surface Antigens - isolation & purification Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Liver Neoplasms - blood Liver Neoplasms - drug therapy Liver Neoplasms - pathology Lymphocyte Count Lymphocytes - drug effects Lymphocytes - pathology Male Middle Aged Neutrophils - drug effects Neutrophils - pathology Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects |
| title | Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A12%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Predictors%20for%20Neutrophil-to-Lymphocyte%20Ratio%20Changes%20in%20Patients%20with%20Chronic%20Hepatitis%20B%20Receiving%20Peginterferon%20Treatment&rft.jtitle=In%20vivo%20(Athens)&rft.au=Le,%20Puo-Hsien&rft.date=2017-07-01&rft.volume=31&rft.issue=4&rft.spage=723&rft.epage=729&rft.pages=723-729&rft.issn=1791-7549&rft.eissn=1791-7549&rft_id=info:doi/10.21873/invivo.11121&rft_dat=%3Cproquest_pubme%3E1914289356%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-abe26fbaf24caba24c72c393623495e22d7da823dba39f8d31e41254892ebde73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1914289356&rft_id=info:pmid/28652447&rfr_iscdi=true |